Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

[Neuromyelitis optica and anti-aquaporin 4 antibody].
Association Between Glutamate Blockade and Fatigue in Patients With Multiple Sclerosis.
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.
Chronic pain following spinal cord injury.
Fatigue in multiple sclerosis: relationship with disease duration, physical disability, disease pattern, age and sex.
Pulmonary Hypertension and Multiple Sclerosis - Coincidence or Association?
Decreased hydrocortisone sensitivity of T cell function in multiple sclerosis-associated major depression.
Efficacy of vision restoration therapy after optic neuritis (VISION study): study protocol for a randomized controlled trial.
Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis.
Acquired perforating dermatosis associated with natalizumab.
Novel Immunomodulatory Approaches for the Management of Multiple Sclerosis.
Complete bilateral horizontal internuclear ophthalmoplegia as a sign of multiple sclerosis relapse.
Self-reported health promotion and disability progression in multiple sclerosis.
[Marihuana and cannobinoids as medicaments].
Vitamin D status and ill health: a systematic review.
The axes of access--improving care for patients with disabilities.
Symptoms, Prevalence and Impact of Multiple Sclerosis in Younger Patients: A Multinational Survey.
Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial.
Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.
Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice.
The Symptom Inventory Disability-Specific Short Forms for Multiple Sclerosis: Construct Validity, Responsiveness, and Interpretation.
Robust Perfusion Deficits in Cognitively Impaired Patients with Secondary-Progressive Multiple Sclerosis.
Multiple sclerosis: Risk factors for progressive multifocal leukoencephalopathy identified in natalizumab-treated patients.
Expanded Disability Status Scale (EDSS) estimation in multiple sclerosis from posturographic data.
Arterial, venous and other vascular risk factors in multiple sclerosis.

Pages